title: Pharmacologic manipulation of steroid hormones. Adjunctive therapies in cancer of the breast.
abstract: Tamoxifen is the endocrine treatment of choice for hormone-responsive early and advanced breast cancer. Newly developed biodegradable luteinizing hormone-releasing hormone super agonists represent a practical and effective treatment for metastatic disease in premenopausal women. Progestins or aromatase inhibitors are useful therapies in patients who relapse from antiestrogens. Currently, there is no indication that improved survival can be achieved by combined endocrine therapy or combined chemo-hormonal therapy.
authors.affiliation: Department of Medicine/Division of Endocrinology, Milton S. Hershey Medical Center, Pennsylvania State College of Medicine, Hershey.
authors.forename: A
authors.initials: A
authors.lastname: Manni
mesh_terms: D047072:Aromatase Inhibitors; D001943:Breast Neoplasms / Q000188:drug therapy*; D004965:Estrogen Antagonists / Q000627:therapeutic use; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D011372:Progestins / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D013256:Steroids / Q000378:metabolism*
chemical_list: D047072:Aromatase Inhibitors; D004965:Estrogen Antagonists; D011372:Progestins; D013256:Steroids; D007987:Gonadotropin-Releasing Hormone